Amazon spent years treating healthcare like a side bet. Tuesday it made it a main event.
Amazon One Medical launched a national GLP-1 weight-loss program. The package combines virtual doctor visits, in-person clinic access, and same-day pharmacy delivery. Oral GLP-1 medications can cost as little as $25 a month for patients with insurance coverage. Without insurance, oral meds run $149 a month cash. Injectables like Wegovy and Zepbound come in at $299 cash.
That pricing undercuts most of the telehealth competition by 20% or more.
Most GLP-1 telehealth programs have one piece of the puzzle. Hims sells prescriptions. LillyDirect sells the drug. Teladoc handles the virtual visits. Nobody stitches it all together cheaply.
Amazon has the stack. One Medical gives it the doctors. Amazon Pharmacy handles fulfillment. Prime gives it the delivery network. The new bit is putting them on one checkout page at one price.
That same-day pharmacy delivery is the part most people miss. By the end of 2026, Amazon expects to offer same-day meds in 4,500 US cities. For a drug that gets refilled every month, that's a big deal.
GLP-1 is a roughly $30 billion US market and still growing fast. The margins for telehealth pure-plays come from two things: price markup on the drug and recurring subscriptions. Amazon just squeezed both.
Eli Lilly sells the injectable drugs. It won a partner, not a competitor. Novo Nordisk, which makes Wegovy, also gets more distribution. The drug makers keep winning either way.
The losers are the middleman companies charging $300 a month for virtual care.
Hims sells a compounded GLP-1 at a monthly price that lives north of Amazon's $149 oral number. Ro's price for its injectable plan sits closer to Amazon's $299, which puts both in the same pricing tier without the Prime delivery stack underneath.
LillyDirect is in a different position because it's the drug maker's own channel. Eli Lilly wins either way, since Amazon pulls Wegovy and Zepbound through its pharmacy at the same list price. Novo Nordisk gets the same benefit on the Wegovy side.
The telehealth pure-play model is the one that gets squeezed. Its margin comes from a markup on the drug plus a recurring subscription, and Amazon just undercut both with a national pharmacy network that same-day delivers in 4,500 cities by end of 2026.
The second-order question is whether Hims and Ro can diversify fast enough. Both are pushing into new drug categories to lean less on GLP-1. Amazon isn't going to slow down and wait for them.
Amazon has tried primary care before. Haven failed. Amazon Care shut down. One Medical was the third attempt, and it's the one that finally clicked.
The GLP-1 program is the first time Amazon is pairing it with a pharmacy business at full national scale. If it works, expect the same playbook for diabetes, mental health, and cardiovascular meds next.
Your next doctor may be in a warehouse.
